| Customization: | Available |
|---|---|
| CAS No.: | 499993-62-3 |
| Formula: | C3h5no4 |
|
Still deciding? Get samples of US$ 0/box
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
FGL is a peptide derived from the neural cell adhesion molecule (NCAM). NCAM is a glycoprotein that is found on the surface of nerve cells (neurons) and glial cells (protect neurons). NCAM activates FGL which in turn stimulates the production of new projections of developing neurons.
FGL also plays a role in the formation of synapses between neurons which results in improved synaptic plasticity and neuronal development. This in combination with enhanced synaptic transmission means FGL can help encode information, resulting in improved learning and memory. Add in neuronal cell protection and preservation and FGL becomes an important peptide with the potential to treat multiple conditions affecting cognitive function.
POTENTIAL BENEFITS
Using the FGL peptide can result in these potential benefits:
GENERIC PEPTIDES (GMP)
| # | Product | Sequence | Therapeutic Area | Form | Unit Size |
| 4109712 | Sema | H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH | Type II diabetes mellitus Obesity |
Lyophilized powder | 2 mg/vial 5 mg/vial 10 mg/vial 15 mg/vial 20 mg/vial 1 g/tube |
| 4109713 | Tirze | H-Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 | Type II diabetes mellitus Obesity |
Lyophilized powder | 10 mg/vial 15 mg/vial 20 mg/vial 30 mg/vial 60 mg/vial 1 g/tube |
| 4109714 | Cagrilintide CAS No.: 1415456-99-3 |
{Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 | Type II diabetes mellitus Obesity |
Lyophilized powder | 5 mg/vial 10 mg/vial 1 g/tube |
| 4109715 | CagriSema | Blend | Type II diabetes mellitus Obesity |
Lyophilized powder | 5 mg/vial 10 mg/vial 20 mg/vial 1 g/tube |
| 4109716 | Retatrutide CAS No. 2381089-83-2 |
Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 | Treatment of type 2 diabetes Treatment of obesity |
Lyophilized powder | 8 mg 10 mg 12 mg 15 mg 1 g/tube |
GMP peptides Manufacturing
Zhaobo Bio acquired early mastery of development and manufacturing of peptides, the short chain amino acids linked by peptide bonds that have enabled new generations of small molecule drugs that closely mimic the body's natural pathways.
Now Zhaobo Bio possesses first-class capabilities to manufacture peptides at industrial scale and in full compliance with the strictest Good Manufacturing Practice (cGMP) standards.
Upstream peptide synthesis
Zhaobo Bio production plants are endowed with state-of-the-art equipment for solvent supply, peptide synthesis, purification and isolation of active ingredients and intermediates. All equipment and containment is GMP qualified and cleaning validated. Overlapping capacities and sizes of different equipment trains facilitate a smooth scale-up for increases in demand within the product life cycle.
Downstream purification and isolation of peptides
Zhaobo Bio is committed to the systematic expansion and modernization of its purification equipment in order to ensure the efficient production of ever-increasing amounts of bulk peptide pharmaceuticals.
It uses sophisticated methods for large scale purification campaigns such as preparative high performance liquid chromatography (HPLC), ion exchange (IEX), size-exclusion chromatography (SEC), and ultra-filtration (UF/TFF). The equipment in place permits highly efficient or even continuous manufacturing of extremely pure products up to multi-kg quantities per lot.
For preparative HPLC, dynamic axial compression (DAC) stainless steel columns of up to 60 cm diameter both in batch and continuous mode are packed with the appropriate high performance silica separation phase. For low-pressure chromatography columns up to 80 cm diameter are available. Solvent delivery is ensured from eluent tank farms and containers.
The control of microbiological contamination is a prerequisite for API manufacturing. Class D (ISO 8) and C (ISO 7) clean rooms are supplied via HEPA-filtered, temperature and humidity controlled air, down-flow booths are used for minimizing microbial contamination and protecting operators. Highly active pharmaceutical ingredients are handled in integrated safety workbenches or flexible isolators reaching OEB level 4 (1-10 µg/m3).
Predefined physicochemical properties of the API can only be achieved by a carefully controlled isolation process. Besides precipitation and crystallization, lyophilization of intermediates and final API is a standard unit operation. LaixingPharma have multiple lyophilizers in different sizes (up to 300 liters) located in clean rooms.
ZhaoboBio's Peptide Plant also manufactures and offers a range of specialized services for the cGMP Small Molecules.
Small molecule production capabilities include: process development, chiral synthesis, heterocyclic chemistry, metal-catalyzed reactions, hydrogenations, oxidations and reductions using various reagents, enzymatic reactions, and high pressure reactions.
){kind=link}